Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer
Abstract
The purpose of this study was to measure genomic changes that emerge with enzalutamide treatment using analyses of whole-genome sequencing and RNA sequencing.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-2303
Entities
People
- Adam Foye
- Alana S Weinstein
- Christopher P Evans
- David A. Quigley
- Duanchen Sun
- Eric J Small
- Eric Lu
- Felix Y. Feng
- George V Thomas
- Jack Youngren
- Jiaoti Huang
- Joshi J Alumkal
- Joshua Urrutia
- Martin Gleave
- Matthew B Rettig
- Primo Lara Jr
- Rahul Aggarwal
- Robert Evan Reiter
- Tomasz M Beer
- William S. Chen
- Xiangnan Guan
- Zheng Xia
Organizations
- National Cancer Institute
- National Institutes of Health
- Oregon Health & Science University
- Stand Up to Cancer
- United States Department of Defense
- University of British Columbia
- University of California, Los Angeles
- University of Michigan Rogel Cancer Center